/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Research To Practice | Oncology Videos · Sep 6, 2026

Expert analysis of CLL trials (Amplify) shows targeted doublets are standard, with triplets for select patients and new combos emerging.

Time-Limited Frontline VEN-BTK Therapy in CLL May Prevent Acquired Drug Resistance Mutations

Clinical data suggests that using time-limited venetoclax-BTK inhibitor combinations in the frontline setting mitigates the emergence of BCL2 or BTK resistance mutations. This provides a key biological rationale supporting this approach, as it preserves future treatment options and allows for successful retreatment.

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 thumbnail

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Research To Practice | Oncology Videos·2 months ago

CLL Treatment Choice Is Shaped by Patient Priorities and "Use-It-or-Lose-It" Reimbursement Policies

Beyond clinical data, treatment decisions are influenced by non-medical factors. Some younger patients prioritize maximum efficacy over the convenience of an all-oral regimen. Additionally, health system policies that restrict funding for drugs like obinutuzumab to frontline use can compel its early adoption to avoid losing it as a future option.

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 thumbnail

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Research To Practice | Oncology Videos·2 months ago

MAGIC Trial's MRD-Guided Design May Obscure Direct Drug Efficacy Comparison in CLL

The MAGIC trial's design, which allows therapy cessation upon achieving undetectable MRD, will likely lead to unequal treatment durations between arms. The Veno-Obinutuzumab arm is predicted to have a shorter (12-month) duration versus the Acalabrutinib-Venetoclax arm (24-month). This difference complicates a direct comparison of the drug combinations themselves.

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 thumbnail

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Research To Practice | Oncology Videos·2 months ago

BTK Inhibitor-Induced Lymphocytosis Is Not a Key TLS Risk Factor for Subsequent Venetoclax Therapy

The transient rise in white blood cell count from BTK inhibitors reflects lymphocyte redistribution, not increased tumor burden. Original TLS risk models, developed in the context of unmodified disease, are less applicable in this debulked state, allowing for a safer initiation of venetoclax ramp-up without waiting for the count to normalize.

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 thumbnail

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Research To Practice | Oncology Videos·2 months ago